Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
- PMID: 23165508
- DOI: VSports app下载 - 10.1002/path.4140
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Abstract
PARP inhibitors (PARPi) for the treatment of BRCA1 or BRCA2 deficient tumours are currently the focus of seminal clinical trials exploiting the concept of synthetic lethality. Although clinical resistance to PARPi has been described, the mechanism underlying this has not been elucidated VSports手机版. Here, we investigate tumour material from patients who had developed resistance to the PARPi olaparib, subsequent to showing an initial clinical response. Massively parallel DNA sequencing of treatment-naive and post-olaparib treatment biopsies identified tumour-specific BRCA2 secondary mutations in olaparib-resistant metastases. These secondary mutations restored full-length BRCA2 protein, and most likely cause olaparib resistance by re-establishing BRCA2 function in the tumour cells. .
Copyright © 2012 Pathological Society of Great Britain and Ireland V体育安卓版. Published by John Wiley & Sons, Ltd. .
Publication types
- "VSports" Actions
MeSH terms (V体育安卓版)
- Actions (VSports)
- VSports - Actions
- "VSports最新版本" Actions
- V体育官网 - Actions
- VSports app下载 - Actions
- VSports手机版 - Actions
- Actions (V体育ios版)
- "V体育ios版" Actions
- "VSports" Actions
- VSports在线直播 - Actions
- Actions (V体育官网入口)
- V体育ios版 - Actions
- "VSports最新版本" Actions
V体育2025版 - Substances
- Actions (VSports注册入口)
- "V体育2025版" Actions
Grants and funding
LinkOut - more resources
"V体育安卓版" Full Text Sources
Other Literature Sources
Miscellaneous
